Inactive Instrument

Highlights Kolon TissueGene, Inc.

Equities

Kolon TissueGene, Inc. Resumes TG-C Phase III Studies in the U.S	28/21/28	CI
Kolon TissueGene, Inc. to Expand Indications for TG-C	04/21/04	CI
Kolon TissueGene, Inc. Announces Plans to Resume US Phase III Clinical Trial For TG-C	13/20/13	CI
Kolon TissueGene, Inc. to Start US Phase III Clinical Trial for Invossa™	06/18/06	CI
Kolon TissueGene, Inc. has completed an IPO in the amount of KRW 202.5 billion.	05/17/05	CI
Kolon TissueGene, Inc. has filed an IPO.	14/17/14	CI
TissueGene, Inc. Announces FDA Acceptance Of Invossa™ as Proprietary Name for TissueGene-C	24/15/24	CI
TissueGene, Inc. Receives Recommendations from FDA on Pathway to Phase 3 Trial of TG-C for Treatment of the Knee	17/14/17	CI
TissueGene, Inc. Announces ELUTE(TM) Biodegradable Drug-Loaded Fiber	09/13/09	CI
TissueGen and Biomedical Structures Announce Availability of Breakthrough Drug Delivery Platform for Implantable Devices	12/13/12	CI
TissueGene, Inc. Completes Enrollment in U.S. Phase II Study of TG-C in Patients with Knee Osteoarthritis	14/12/14	CI

No results for this search